Weight-Loss Pills vs Injections: Which?

The route alone does not determine which weight-loss medicine works best. Oral and injectable options differ in molecule, approved use, effectiveness, risks and administration requirements.

Approved oral options

Long-term weight-management options include orlistat, phentermine/topiramate, naltrexone/bupropion and Wegovy tablets. FDA also approved Foundayo (orforglipron) on April 1, 2026. It is therefore no longer accurate to describe Wegovy as the only oral GLP-1 option for obesity. Indications, precautions and approved ages depend on the product. FDA: Foundayo approval Contrave: prescribing information Adipex-P: prescribing information Wegovy: prescribing information

The classes work differently

Orlistat reduces fat absorption. Phentermine/topiramate and naltrexone/bupropion use other appetite-related pathways. GLP-1 receptor agonists influence appetite and glucose regulation. Phentermine alone is approved for short-term use; it should not be confused with a combination approved for long-term use. Source: NIDDK: prescription weight-management medicines

Pill versus injection: compare the product

Route alone cannot rank medicines by effectiveness or tolerability. Administration rules also vary: semaglutide tablets have fasting instructions, but not every pill shares that schedule. A milligram dose of one product does not equal the same number for another. Do not convert oral and injectable doses yourself.

What a trial can establish

Trials inform the studied product, dose and population. Comparing percentages across different trials does not establish treatment equivalence. In particular, OASIS 1 studied oral semaglutide 50 mg: it should not be presented as the approved Wegovy tablet dose or as evidence for a compounded preparation.

Compounded oral preparations

A compounded oral preparation is not Wegovy, Ozempic or Rybelsus and does not have their approval. Approval of a molecule in one product does not transfer to another formulation. Source: FDA: unapproved GLP-1 medicines

Questions to discuss with your clinician

Review the indication, history, interactions, risks, daily routine, ongoing cost and follow-up. Ask how response will be assessed and when the plan would change. Review REMEVi’s oral semaglutide options, which are compounded preparations distinct from approved tablets.